C4 Therapeutics IPO

10/1/2020

IPO

$182,400,000

Management says it will use the net proceeds from the IPO as follows:approximately $40.0 million to complete the Phase 1 portion of our planned first-in-human Phase 1/2 clinical trial of CFT7455 for patients with MM or NHL, such as PTCL or MCL, as well as to fund a portion of the Phase 2 expansion component of that clinical trial in these indications;approximately $56.0 million to complete the Phase 1 portion of our planned first-in-human Phase 1/2 clinical trial of CFT8634 for patients with synovial sarcoma or solid tumors with SMARCB1 loss, as well as to fund a portion of the Phase 2 expansion component of this trial and initiate a Phase 3 confirmatory clinical trial of this product candidate in synovial sarcoma;approximately $62.0 million to conduct and complete IND-enabling studies with respect to BRAF V600E and RET, substantially complete the Phase 1 portion of our planned first-in-human Phase 1 /2 clinical trials for each of these programs and fund initial portions of our planned

Publicly-held

Biopharmaceutical

490 Arsenal Way 200
Watertown, MA 02472
USA

Not Recorded

C4 Therapeutics (Nasdaq: CCCC) is developing a new class of targeted protein degradation (TPD) therapeutics for the treatment of a broad range of diseases.